Biomarin Pharmaceutical (BMRN) Interest Expenses (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Interest Expenses data on file, last reported at $17.4 million in Q1 2026.

• Quarterly Interest Expenses rose 508.0% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.4 million (up 42.95% YoY) and the FY2025 annual result came in at $181.7 million, up 43.89% from the prior year.
• Interest Expenses grew to $17.4 million in Q1 2026, from $1.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $17.4 million in Q1 2026 to a low of -$510000.0 in Q4 2023.
• A 5-year average of $4.0 million and a median of $3.6 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses plunged 114.07% — and 2024, when it jumped 605.29%.
• Tracing BMRN's Interest Expenses over 5 years: stood at $3.6 million in 2022, then tumbled by 114.07% to -$510000.0 in 2023, then jumped by 605.29% to $2.6 million in 2024, then plunged by 52.62% to $1.2 million in 2025, then jumped by 1325.63% to $17.4 million in 2026.
• The last three Interest Expenses figures came in at $17.4 million (Q1 2026), $1.2 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.